✦ LIBER ✦

Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer

✍ Scribed by Sitvana Martino; Bohumil A. Samal; Bruce Redman; Lawrence Flaherty; Michael Kraut; Michael Simon; Manuel Valdivieso

Publisher: Springer US
Year: 1990
Tongue: English
Weight: 425 KB
Volume: 17
Category: Article
ISSN: 0167-6806
DOI: 10.1007/bf01806294

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study with etoposide in previou

Phase II study with etoposide in previously untreated advanced breast cancer

✍ Hans-Erik Wander; Winrich Rauschning; Dirk Meyer; Wolfgang Achterrath; Gerd-Arno 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 281 KB

Carboplatin activity in untreated metast

Carboplatin activity in untreated metastatic breast cancer patients — results of a phase II study

✍ K. Kolarić; D. Vukas 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 388 KB

Phase II study of deoxyspergualin in met

Phase II study of deoxyspergualin in metastatic breast cancer

✍ Kapil Dhingra; Vicente Valero; Lia Gutierrez; Richard Theriault; Daniel Booser; 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 553 KB

Phase II clinical trial ofcis-dichlorodi

Phase II clinical trial ofcis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer

✍ Krsto Kolarić; Anton Roth 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 467 KB

Trimetrexate in untreated and previously

Trimetrexate in untreated and previously treated patients with metastatic breast cancer: A cancer and leukemia group b study

✍ Dawson, Nancy A. ;Costanza, Mary E. ;Korzun, Ann H. ;Clamon, Gerald H. ;Pollak, 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 554 KB

Twenty-two patients with previously untreated metastatic breast cancer and nineteen patients with refractory metastatic breast cancer were treated with trimetrexate (TMTX). Patients received TMTX 8 mg/m2/day if previously treated or 12 mg/m2/day if previously untreated, both given by intravenous bol

Phase II study of ionidamine in patients

Phase II study of ionidamine in patients with metastatic breast cancer

✍ H. Ian Robins; Donna S. Neuberg; Al B. Benson; Kishan J. Pandya; Douglass C. Tor 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 193 KB

The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m 2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxi